Medtronic (MDT) announced CE Mark approval in the European Union and the United Kingdom for BrainSense Adaptive deep brain stimulation and BrainSense Electrode Identifier, having achieved the standards required by the EU Medical Device Regulation. In addition, the first programming was completed, performed by Martijn Beudel, neurologist and associate professor, Department of Neurology, Amsterdam University Medical Center.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic price target lowered to $93 from $97 at Bernstein
- J&J pause ‘very good’ for Boston Scientific, says Piper Sandler
- Early notable gainers among liquid option names on January 8th
- Medtronic price target lowered to $89 from $93 at Truist
- Acutus Medical announces downsizing, sees $1.4 M-$1.8M in charges